What is the NOVELTY study?
NOVELTY (NOVEL observational longiTudinal studY) is a global, prospective, 3-year study of patients with a physician-assigned diagnosis of asthma and/or chronic obstructive pulmonary disease (COPD), with an additional extension study visit at participating sites.
NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, to re-frame obstructive lung disease by enabling the move towards a preventive- and precision medicine-led clinical paradigm. The NOVELTY study is sponsored by AstraZeneca.
The NOVELTY website
Watch our short animation to learn more about the NOVELTY study
NOVELTY study infographic
NOVELTY is a global, prospective, observational study, which followed ~12,000 patients for up to 3 years.
NOVELTY extension study
An extension period is now underway for the NOVELTY study, enrolling patients from participating sites for up to 2 years of follow-up.
The Advanced Diagnostic Profiling (ADPro) sub-study is now underway in the UK.
NOVELTY baseline characteristics
An article reporting the baseline characteristics data of the global population of patients participating in the NOVELTY study has been published in the European Respiratory Journal.
Respiratory Symptoms Questionnaire
An article examining the reliability and validity of the novel Respiratory Symptoms Questionnaire (RSQ) in patients with asthma and/or COPD in the NOVELTY study has been published in ERJ Open Research.